BeyondSpring
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 36
- Market Cap
- -
- Introduction
BeyondSpring, Inc. engages in the development and commercialization of immuno-oncology cancer therapies. It operates through the Plinabulin Pipeline and TPD Platform segments. The Plinabulin Pipeline segment focuses on the development of cancer therapies. The TPD Platform segment engages in the development of therapeutic agents and discover chemical entities. The company was founded by Lan Huang and Lin Qing Jia in 2010 and is headquartered in Florham Park, NJ.
Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2
- Conditions
- Chemotherapy-induced Neutropenia
- Interventions
- First Posted Date
- 2020-04-15
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- BeyondSpring Pharmaceuticals Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT04345900
- Locations
- 🇺🇸
Emad Ibrahim, MD, Inc., Redlands, California, United States
🇺🇸Mid Florida Hematology & Oncology Center, Orange City, Florida, United States
🇺🇸Cancer Center of Middle Georgia, Dublin, Georgia, United States
Plinabulin iv Solution in Prevention of TAC Induced Neutropenia
- Conditions
- Chemotherapy-induced Neutropenia
- Interventions
- First Posted Date
- 2020-01-14
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- BeyondSpring Pharmaceuticals Inc.
- Target Recruit Count
- 115
- Registration Number
- NCT04227990
- Locations
- 🇨🇳
Cancer Center of Guangzhou Medical University Breast Oncology, Guangzhou, Guangzhou, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Harbin, China
🇨🇳Fourth Hospital of Hebei Medical University Breast cancer department, Shijiazhuang, Hebei, China
Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia
- Conditions
- Chemotherapy-induced Neutropenia
- Interventions
- First Posted Date
- 2017-09-27
- Last Posted Date
- 2021-01-15
- Lead Sponsor
- BeyondSpring Pharmaceuticals Inc.
- Target Recruit Count
- 221
- Registration Number
- NCT03294577
- Locations
- 🇨🇳
No. 1 Banshandong Road, Hangzhou, Gongshu District, China
🇨🇳Cancer Center of Guangzhou Medical University, Guangzhou, Guangdong, China
🇨🇳Cancer Center of Guangzhou Medical University Breast Oncology, Guangzhou, Guangzhou, China
Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3
- Conditions
- Chemotherapy-induced Neutropenia
- Interventions
- First Posted Date
- 2017-04-06
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- BeyondSpring Pharmaceuticals Inc.
- Target Recruit Count
- 105
- Registration Number
- NCT03102606
- Locations
- 🇺🇸
Stanford University School of Medicine - Cancer Institute, Stanford, California, United States
🇺🇸Hematology/Oncology of the North Shore, Skokie, Illinois, United States
🇺🇸Norton Cancer Institute, Louisville, Kentucky, United States
Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2015-07-22
- Last Posted Date
- 2022-09-10
- Lead Sponsor
- BeyondSpring Pharmaceuticals Inc.
- Target Recruit Count
- 559
- Registration Number
- NCT02504489
- Locations
- 🇺🇸
Ironwood Cancer & Research Centers, Chandler, Arizona, United States
🇺🇸Pacific Cancer Medical Center, Inc., Anaheim, California, United States
🇺🇸Innovative Clinical Research Institute, Whittier, California, United States